Nexus Surgical and Medicare Limited Fundamental Analysis (BSE: NEXUSSURGL.BO)
Nexus Surgical and Medicare Limited Fundamental Analysis (BSE: NEXUSSURGL.BO)
Nexus Surgical and Medicare Limited (BSE: NEXUSSURGL.BO) shows moderate financial fundamentals with a PE ratio of 13.53, profit margin of 9.07%, and ROE of 55.57%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 70.7/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze NEXUSSURGL.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentNEXUSSURGL.BO demonstrates superior asset utilization.
Valuation Score
ExcellentNEXUSSURGL.BO trades at attractive valuation levels.
Growth Score
ModerateNEXUSSURGL.BO shows steady but slowing expansion.
Financial Health Score
ExcellentNEXUSSURGL.BO maintains a strong and stable balance sheet.
Profitability Score
WeakNEXUSSURGL.BO struggles to sustain strong margins.
Key Financial Metrics
Is NEXUSSURGL.BO Expensive or Cheap?
P/E Ratio
NEXUSSURGL.BO trades at 13.53 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, NEXUSSURGL.BO's PEG of 0.34 indicates potential undervaluation.
Price to Book
The market values Nexus Surgical and Medicare Limited at 5.93 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 11.12 times EBITDA. This signals the market has high growth expectations.
How Well Does NEXUSSURGL.BO Make Money?
Net Profit Margin
For every $100 in sales, Nexus Surgical and Medicare Limited keeps $9.07 as profit after all expenses.
Operating Margin
Core operations generate 11.51 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $55.57 in profit for every $100 of shareholder equity.
ROA
Nexus Surgical and Medicare Limited generates $21.58 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Nexus Surgical and Medicare Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Nexus Surgical and Medicare Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
NEXUSSURGL.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
13.53
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.34
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.93
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.23
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.96
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.56
vs 25 benchmark
ROA
Return on assets percentage
0.22
vs 25 benchmark
ROCE
Return on capital employed
0.56
vs 25 benchmark
How NEXUSSURGL.BO Stacks Against Its Sector Peers
| Metric | NEXUSSURGL.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 13.53 | 30.97 | Better (Cheaper) |
| ROE | 55.57% | 515.00% | Weak |
| Net Margin | 9.07% | 30197.00% | Weak |
| Debt/Equity | 0.00 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 1.96 | 5.71 | Neutral |
| ROA | 21.58% | -16.00% (disorted) | Strong |
NEXUSSURGL.BO outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Nexus Surgical and Medicare Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation